Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) 69.6% LOWER; announced top-line results from its Phase 3 clinical trial in adults with drug-resistant ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE